The American Society of Transplantation Online Transplant Infectious Diseases Library
Full Library 1,578 resources
-
Cytomegalovirus (CMV) is one of the most common infections occurring after solid organ transplantation. This high burden of disease, which incurs sizeable morbidity, may be worsening with the proportion of high-risk D+/R− solid organ transplantation recipients increasing in some regions globally. Cohort studies continue to support either universal prophylaxis or preemptive therapy as effective prevention strategies. Letermovir prophylaxis was noninferior to valganciclovir in adult high-risk...
-
Abstract Background Epstein–Barr virus (EBV)‐associated post‐transplant lymphoproliferative disorders (PTLD) is the most common malignancy in children after transplant; however, difficulties for early detection may worsen the prognosis. Methods The prospective, multicenter, study enrolled 944 children (≤21 years of age). Of these, 872 received liver, heart, kidney, intestinal, or...
-
Background: This study aims to compare the infections’ risk between adolescents and young adults (AYAs), treated for acute lymphoblastic leukemia, and pediatric population. We also focused on their bacterial and fungal infection specificities. Methods: This case–control study investigated the occurrence of bacterial bloodstream infection (BSI) and proven and probable invasive fungal infection (IFI) in AYAs (15–25 years...
-
Heart failure (HF) is a frequent cause of inpatient admissions. The Framingham study in 1993 described the risk factors for heart failure and showed unacceptably high five-year mortality rates of 25% in men and 38% in women . The American Heart Association reported the prevalence of HF to be 5.1 million in the United States in 2006 . The worldwide prevalence has been estimated to be 23 million . HF can be categorized based on the left ventricular ejection fraction (LVEF) into systolic and...
-
Abstract Chronic GVHD (cGVHD) is the most relevant cause of late non-relapse morbidity and subsequent mortality (approximately 25%) following allo-HCT (Grube et al. 2016). Its incidence is approximately 50% among all patients following allo-HCT and has increased during the last two decades due to increasing patient age and increasing use of unrelated and/or mismatched donors, RIC regimens, PBSC with application of standard GVHD prophylaxis (calcineurin inhibitor [CNI] + MMF or...
-
The detection of letermovir and maribavir resistance mutations highlights an ongoing clinical challenge in the management of CMV.
-
Background: Cytomegalovirus (CMV) infection has broad implications for morbidity and mortality in renal transplant recipients (RTR). Routine surveillance for CMV replication with PCR-based quantitative nucleic acid testing (qNAT) assays is standard practice in most transplant centers, but the impact of assay sensitivity on antiviral decisionmaking and virologic outcomes has not been studied. We investigated the effects of an ultrasensitive CMV qNAT assay on multiple clinical outcomes,...
-
Background. Surgical-site infections (SSIs) are common in liver transplant recipients. The optimal SSI antimicrobial prophylaxis agent and duration are not established. We aimed to explore risk factors for SSIs after transplant, with a particular interest in the impact of perioperative antibiotic regimen on the development of SSIs. Methods. Retrospective study of adults undergoing liver transplant across 3 transplant...
-
Infection is a common complication in kidney transplant recipients (KTRs). The usefulness of antimicrobial stewardship programs (ASP) and hospital-acquired infection control (HAIC) initiatives in the general inpatient population is well established. We performed a quasi-experimental study to evaluate a joint ASP/HAIC initiative focused on KTRs. A dedicated ASP team optimized antimicrobial prescriptions in consecutive KTRs during the intervention period (June 2015-March 2016). A multifaceted,...
-
Background. Neutropenia may limit use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy of maribavir with fewer treatment-limiting toxicities than valganciclovir. Methods. In this multicenter, double-blind, phase 3 study, patients with first asymptomatic CMV infection post-HCT were stratified and randomized 1:1 to maribavir 400 mg twice daily or valganciclovir (dose-adjusted for renal clearance)...
-
Among 292 allogeneic hematopoietic cell transplant recipients (allo-HCTr, 2018-2022), 64 (21.9%) tested positive for anti-HEV-IgG and among 208 allo-HCTr tested by plasma/serum-HEV-PCR (2012-2022) 3 (1.4%) primary HEV infections were diagnosed; in one patient plasma HEV-PCR relapsed positive for 100 days. HEV infection remains rare albeit associated with persistent viral replication.
-
A transplant infectious disease (TID) assessment is essential to select recipients for an allogeneic-hematopoietic cell transplant (HCT) and tailor prophylactic and empirical treatment recommendations.We performed a retrospective single-center study to describe our model of care based on a routine TID consultation prior to an allogeneic-HCT between 2018 and 2022 in 292 adult (≥18-year-old) consecutive patients. We describe the performance of a TID consultation, arbitrarily defined as major...
-
Background. The gap between demand and supply for solid organ transplants requires strategies to expand the donor pool. Successful use of hepatitis B virus (HBV)-positive grafts has been reported in liver transplantation. Methods. In this United Network for Organ Sharing database (January 1999 to June 2021) retrospective cohort study, outcomes of kidney transplant (KT) or heart transplant (HT) recipients with HBV donor...
Filter by our tag
GUIDELINES
- AASLD Guidelines (9)
- AST Guidelines 2019 (44)
- ASTCT Guidelines (14)
- ECIL Guidelines (20)
- ESCMID Guidelines (25)
- IDSA Guidelines (45)
- ISHLT Guidelines (12)
- TTS Guidelines (2)
- WikiGuidelines (3)
TEXTBOOKS
CORE CURRICULUM
- INTRO LVAD AND MCSS (4)
- INTRO MALIGNANT HEME, HSCT, CAR-T (10)
- INTRO SOLID ORGAN TRANSPLANT (20)
- ORGANISMS (41)
-
SYNDROMES
(16)
- CNS (2)
- Diarrhea (3)
- Neutropenic Fever (2)
- Pneumonia (7)
- UTI (2)
ORGANISMS
-
BACTERIA
(160)
- C. difficile (25)
- Legionella (1)
- MDR GNR (37)
- MRSA (7)
- Mycoplasma and Ureaplasma (11)
- Nocardia (11)
- Non-tuberculous Mycobacteria (27)
- Syphilis (6)
- Tuberculosis (35)
- VRE (8)
-
FUNGI
(218)
- Aspergillus (57)
- Candida (41)
- Cryptococcus (29)
- Dimorphic mycoses (42)
- Mucormycosis (34)
- Pneumocystis (39)
- Rarer Fungi (23)
-
PARASITES AND PROTOZOA
(44)
- Chagas (10)
- Protozoa (12)
- Strongyloides (14)
- Toxoplasmosis (12)
-
VIRUSES
(415)
- Adenovirus (17)
- Arboviruses (7)
-
CMV
(121)
- Cell-Mediated Immunity Assays (11)
- Clinical (55)
- Cytotoxic T-Lymphocytes (1)
- Epidemiology and Risk Factors (15)
- Letermovir (26)
- Maribavir (17)
- Preemptive Therapy (7)
-
COVID-19
(45)
- Diagnosis (3)
- Fungal superinfection (2)
- GUIDELINES (9)
- Infection Prevention (3)
- Positive Donors (6)
- Positive Recipients (5)
- Treatments (18)
- Vaccination (8)
- Hepatitis A (2)
- Hepatitis B (27)
- Hepatitis C (31)
- Hepatitis D (5)
- Hepatitis E (5)
- HHV-6 (24)
- HHV-8 (4)
- HIV (31)
- HPV (5)
- HSV (4)
- Influenza (17)
- Measles (22)
- Mpox (6)
- Norovirus (8)
- Parvovirus B19 (3)
- Polyomaviruses (32)
- Respiratory Viruses (32)
- RSV (18)
- VZV (17)
- WNV (2)
DIAGNOSTICS
- Advanced Diagnostics (23)
- Fungal diagnostics (41)
- Nuclear Medicine (7)
- Parasites (3)
- Procalcitonin (1)
- Viral diagnostics (1)
DRUGS AND THERAPIES
- Antibiotics (12)
- Antifungals (66)
- Antivirals (10)
- Cytotoxic T-lymphocyte therapy (8)
- Fecal Microbiota Transplantation (12)
- Phage therapy (4)
- Stewardship (57)
PREVENTION
- Infection Control (8)
- Safe Living (22)
- Travel (10)
- Vaccination (40)
SYNDROMES AND CONDITIONS
- Cirrhotics (12)
- CNS (3)
- Cytopenias (2)
- Diarrhea (13)
- Endovascular infections (12)
- Osteomyelitis and Diabetic Foot Infection (3)
- Pneumonia (11)
- Surgical Infections (3)
- UTI (32)
SOLID ORGANS AND MCSS
- Donor (43)
- Heart (14)
- Immunosuppression (14)
- Intestinal (2)
- Kidney (32)
- Liver (53)
- Lung (70)
- LVAD (30)
- Pancreas (5)
- PEDIATRIC (43)
- Recipient (5)
- Total Artificial Heart (1)
- Vascular Composite Allograft (2)
- Xenotransplantation (3)
HEME-ONC AND CELLULAR THERAPIES
- Biologics (45)
- BMT Basics (4)
- BMT Guidelines (14)
- BMT Noninfectious (10)
- BMT-specific ID (71)
- CAR-T (22)
- CAR-T Noninfectious (6)
- GVHD (6)
- Heme malignancies (4)
- Heme-onc prophylaxis (23)
- Neutropenia (40)
- PEDIATRIC (33)
- PTLD (24)
- TK inhibitors (12)
TRANSPLANT ID TRAINING
- AST (4)
- Career Development (2)
- Fungal (4)
- Training program (7)
PATIENT EDUCATION
- COVID-19 (13)
- Food (13)
- Hygiene (7)
- Mpox (5)
- Outdoor activities (3)
- PATIENT INFORMATION SHEETS (16)
- Pets (6)
- Safer living (22)
- Selected Infections (10)
- TB (10)
- Travel (6)
- Water safety (7)
- Workplace safety (3)
JOURNAL CLUB
- 2024 (2)